{"id":"smarca2","name":"SMARCA2","symbol":"SMARCA2","route":"/targets/smarca2/","asOf":"2026-09-23","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11098","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080503","uniprot":"https://www.uniprot.org/uniprotkb/P51531/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P51531","open-targets":"https://platform.opentargets.org/target/ENSG00000080503","civic":"https://civicdb.org/genes/6595/summary","oncokb":"https://www.oncokb.org/gene/SMARCA2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMARCA2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=SMARCA2","depmap":"https://depmap.org/portal/gene/SMARCA2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000080503-SMARCA2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/6595","omim":"https://www.omim.org/entry/600014"}],"products":[{"id":"fhd-909","name":"FHD-909","status":"phase-1","modality":"Oral small-molecule allosteric inhibitor","route":"/drugs/fhd-909/"},{"id":"plx-61639","name":"PLX-61639","status":"phase-1","modality":"Oral monovalent direct protein degrader","route":"/drugs/plx-61639/"}],"trials":[{"id":"nct06561685","name":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","nct":"NCT06561685","phase":"1","status":"recruiting"},{"id":"nct07284186","name":"First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors","nct":"NCT07284186","phase":"1","status":"recruiting"}],"pathways":[],"companies":["foghorn-therapeutics","plexium"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}